While addition of anti-IL-7Rα antibodies to antigen-specific immunotherapy altered parameters such as antigen-specific T cell numbers and Treg proliferation in a favorable way to potentially improve therapeutic efficacy, the combination nevertheless failed to provide increased protection against T1D in the NOD model. The gene discussed is IL7R; the disease is type 1 diabetes mellitus.